Stock AnalizNutex Health Inc. NUTX
Business Services · data as of November 13, 2026
Nutex Health Inc. (NUTX) is a consumer discretionary company listed in the US with a market value of about $1.2B. In the twelve months to September 30, 2026 it had revenue of $797M and net income of $165M, a net margin of 20.7%.
Its overall Stock Analiz score is 3.6 out of 5 (good). The strongest part is value (5/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 7.5, a price to free cash flow of 4.8, 5-year revenue growth of 26% a year, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 44% above the current price.
Score: 3.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Checks not passed
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $797M | $875M | $480M | $248M | $219M | $332M | $274M | $1M | $1M | — | $0 |
| Net income | $165M | $71M | $52M | -$46M | -$425M | $133M | $106M | -$7M | -$950129 | $582062 | -$7M |
| Free cash flow | $248M | $246M | $21M | -$8M | $36M | $137M | $25M | -$4M | -$480049 | — | — |
| EPS (diluted) | $23.22 | $10.48 | $9.69 | $-10.39 | $-100.36 | $0.22 | $0.18 | $-1.96 | $-0.56 | $0.84 | $-16.04 |
| Net margin | 20.7% | 8.1% | 10.8% | -18.5% | -193.7% | 40.0% | 38.7% | -520.8% | -69.5% | — | — |
| ROIC | — | 50.1% | 54.6% | -23.5% | -206.8% | 83.1% | — | -276.0% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $313.67, 81% above the current price; targets range from $250.00 to $357.00; the consensus rating is “Strong buy”; expected EPS is $27.37 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Nutex Health’s P/E ratio?
About 7.5, based on the last twelve months of diluted earnings per share (forward P/E about 6.5).
Is Nutex Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 44% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Nutex Health pay a dividend?
Not currently.
Is Nutex Health a good stock to buy?
We do not give buy or sell advice. Nutex Health scores 3.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.